Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT K642E | melanoma | predicted - sensitive | Imatinib | Case Reports/Case Series | Actionable | In a Phase II trial, Gleevec (imatinib) treatment resulted in a durable objective response rate of 16% (4/25, 2 complete and 2 partial responses), a median time-to-progression of 12 weeks, and a median survival from treatment initiation of 46.3 weeks in patients with melanoma harboring KIT mutations, including 1 partial response, 1 transient partial response, and 2 stable disease in patients harboring KIT K642E (PMID: 21642685; NCT00470470). | 21642685 |
PubMed Id | Reference Title | Details |
---|---|---|
(21642685) | KIT as a therapeutic target in metastatic melanoma. | Full reference... |